Sign in
Active, not recruitingPhase 4

Beta-lactam Intermittent Versus Continuous Infusion and Combination Antibiotic Therapy in Sepsis

Key facts

Who runs it
Assistance Publique - Hôpitaux de Paris
Where
France26 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 4
People taking part
600 people, planned
Started
13 Nov 2023
Expected to end
4 Mar 2027
Type of study
Interventional, 4 groups
Treatments tested
  • continuous pivotal βL-AB
  • intermittent pivotal βL-AB
  • AG infusion most 1 dose
  • AG infusion for 5 days
Record updated
16 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Adults (≥ 18 years)
  • Hospital-acquired sepsis (according to sepsis 3.0 definitions) :; Patient hospitalized for more than 48 hours OR Patient discharged less than 48 hours ago; AND sepsis diagnosed within the last 24 hours
  • One of the following risk factors for gram negative multidrug resistant pathogens:; Prior intravenous antibiotic use within 7 days prior to sepsis onset with the exception of antibiotic effective only against Gram-positive bacteria, penicillin A and macrolides; Prolonged hospital stay (≥ 15 days of hospitalization) within 3 months prior to sepsis onset Prolonged mechanical ventilation (≥ 5 days on mechanical ventilation) within 3 months prior to sepsis onset; Patients with indwelling devices (dialysis access lines, intravascular lines, urinary catheter, endotracheal or tracheostomy tube, gastrostomy or jejunostomy feeding tube); Patients known to be infected, colonized or carriers of MDR gram negative bacteria within 3 months prior to sepsis onset; Exposure to an antibiotic (amoxicillin-clavulanic acid, C2G, C3G, fluoroquinolones) within 3 months prior to sepsis onset; A trip abroad to known geographical areas at risk (in particular the Indian subcontinent, South-East Asia, the Middle East and North Africa, the Mediterranean Basin) within 3 months prior to sepsis onset; A functional or organic abnormality of the urinary tract in case of urinary tract infection
  • Appropriate bacteriological sampling performed before starting antimicrobial therapy
  • Expected stay in ICU of more than 3 days

Who cannot take part

  • Bone marrow transplant or chemotherapy-induced neutropenia
  • Enrolment to another interventional drug study
  • Known hypersensitivity to ceftazidime, piperacillin-tazobactam, cefepime, meropenem, ceftazidime-avibactam, ceftazolane-avibactam or to any of the excipients included in the corresponding pharmaceutical drugs,
  • Known hypersensitivity to any cephalosporin antibacterial agent,
  • Severe known hypersensitivity (eg, anaphylactic reaction, severe skin reaction) to any other beta-lactam antibiotic (eg, penicillins or monobactam ) or to any of its excipients
  • Known contraindication to the aminoglycoside family including; Hypersensitivity to the active substance, to any aminoglycoside antibacterial agent or to any of the excipients included in the corresponding pharmaceutical drugs,; Cirrhosis of grades B and C according to the Child-Pugh classification; Myasthenia gravis; Simultaneous administration of another aminoglycoside; Association with ataluren
  • Non-complicated urinary tract infection (corresponding to a positive ECBU not responsible for sepsis)
  • Infections for which long-term antibiotic treatment > 8 days is strongly recommended (i.e., infective endocarditis, osteoarticular infections, anterior mediastinitis after cardiac surgery, hepatic or cerebral abscesses, chronic prostatitis for instance
  • A priori known resistance to all the proposed beta-lactams or to amikacin
  • Need for extrarenal treatment at inclusion according to the criteria of Gaudry et al
  • Know hypersentitivity to any penem antibacterial agent,
  • Presence of antibiotic therapyfor the new sepsis before randomisation: (> 2 doses of antibiotics or > 16h for continuous infusion
  • Limitation of life support (comfort care applied only) at the time of screening
  • Pregnancy or breastfeeding
  • Subject deprived of freedom, subject under a legal protective measure
  • Non affiliation to any health insurance system
  • Refusal to participate to the study (patient or legal representative or family member or close relative if present)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Patients hospitalized in ICU with sepsis (infection with life-threatening organ dysfunction according to sepsis 3.0 definitions) or septic shock presumably due to MDR-GNB (multidrug resistant Gram-negative bacteria). The study will be a prospective multicentre, randomized, open-label comparative continuous vs. intermittent pivotal βL (Beta Lactamine) antibiotic infusion strategies and combination vs. monotherapy trial conducted with a 2X2 factorial design.

The 4 groups in the trial

  • continuous infusion dosing of a pivotal AND AG infusion for 5 daysTreatment being tested

    continuous infusion dosing of a pivotal βL-AB (CID group) AND AG infusion for 5 days (long duration) as appropriate combination therapy (ACT group)

    Treatment: continuous pivotal βL-AB and AG infusion for 5 days

  • intermittent infusion dosing of a pivotal βL-AB ND AG infusion for 5 daysTreatment being tested

    intermittent infusion dosing of a pivotal βL-AB (IID = control group) AND AG infusion for 5 days (long duration) as appropriate combination therapy (ACT = group)

    Treatment: intermittent pivotal βL-AB and AG infusion for 5 days

  • continuous infusion dosing of a pivotal βL-AB AND AG infusion at most 1 doseTreatment being tested

    continuous infusion dosing of a pivotal βL-AB (CID group) AND AG infusion at most 1 dose (AMT group )

    Treatment: continuous pivotal βL-AB and AG infusion most 1 dose

  • intermittent infusion dosing of a pivotal βL-AB AND AG infusion at most 1 doseTreatment being tested

    intermittent infusion dosing of a pivotal βL-AB (IID = group) AND AG infusion at most 1 dose (AMT group)

    Treatment: intermittent pivotal βL-AB and AG infusion most 1 dose

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
16 October 2026